Phase 2 Nerve Growth Factor (Cerebrolysin®) for Treatment of Neonatal Hypoxic Ischemic Encephalopathy

Sahar M.A. Hassanein, MD1 site in 1 country40 target enrollmentMarch 2011

ConditionsHypoxic-Ischemic Encephalopathy

InterventionsCerebrolysin®

DrugsCerebrolysin®

Overview

Phase: Phase 2
Intervention: Cerebrolysin®
Conditions: Hypoxic-Ischemic Encephalopathy
Sponsor: Sahar M.A. Hassanein, MD
Enrollment: 40
Locations: 1
Primary Endpoint: Side effects during cerebrolysin therapy (one course).
Status: Completed
Last Updated: 12 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to determine whether nerve growth factor (cerebrolysin®) therapy will improve the psychomotor outcome in infants with moderate and severe hypoxic ischemic encephalopathy after hospital discharge.

Detailed Description

Infants with perinatal history of moderate to severe Hypoxic ischemic encephalopathy HIE will receive 10 injections of cerebrolysin IM. Assessment of neurodevelopment will be done before , 3 and 6 months after therapy

Registry

clinicaltrials.gov

Start Date

March 2011

End Date

September 2013

Last Updated

12 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Sahar M.A. Hassanein, MD

Responsible Party

Sponsor Investigator

Principal Investigator

Sahar M.A. Hassanein, MD

Professor of Pediatrics, Children's Hospital, Faculty of Medicine

Ain Shams University

Eligibility Criteria

Inclusion Criteria

•Infant aged 3-6 months with perinatal history of moderate or severe HIE collected from his NICU's file. Criteria of neonatal asphyxia and encephalopathy according to the American College of Obstetricians and Gynecologist and American Academy of Pediatrics, metabolic acidosis with a cord pH of 7.0 or less or a base deficit of at least 12 mmol/L, early onset of encephalopathy, and multisystem organ dysfunction with exclusion of other possible causes for findings.
•Criteria of neonatal asphyxia:
•Full term neonate more than 36 weeks of gestation
•pH of 7.0 or less or a base deficit of 16 mmol per liter or more in a sample of umbilical-cord blood or any blood during the first hour after birth.
•If, during this interval, a pH is between 7.01 and 7.15, a base deficit is between 10 and 15.9 mmol per liter, or a blood gas is not available, additional criteria are required. These includes an acute perinatal event (e.g., late or variable decelerations, cord prolapse, cord rupture, uterine rupture, maternal trauma, hemorrhage, or cardiorespiratory arrest) and either a 10-minute Apgar score of 5 or less or assisted ventilation initiates at birth and continues for at least 10 minutes.
•Criteria of neonatal encephalopathy according to Sarnat and Sarnat. Presence of one or more signs in at least three of the following six categories:
•level of consciousness.
•spontaneous activity.
•primitive reflexes (suck or Moro.
•autonomic nervous system (pupils, heart rate, or respiration). The number of moderate or severe signs determined the extent of encephalopathy; if signs were equally distributed, the designation was based on the level of consciousness.